Investigational drug · Phase 2
NEO212
Also called: POH-TMZ
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NEO212"
First trial start
2023
Nov 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NEO212", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Astrocytoma, IDH-Mutant
- Glioblastoma, IDH-wildtype
- Brain Metastases, Adult
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Head and neck cancer · Cervical cancer · Brain tumors (glioma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NEO212" as an intervention, largest first.
Neonc Technologies, Inc.Industry
NCT06047379 · 134 participants (planned) · Start Nov 1, 2023 · Primary completion Feb 28, 2027
Drug: NEO212 Oral Capsule; Ipilimumab and 7 more · For: Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult and 18 more
Sites: Beverly Hills, California; Glendale, California; Los Angeles, California · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma.
Chen TC, Swenson S, Thein TZ, et al. · Vet Comp Oncol 2025
- NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma.
Minea RO, Thein TZ, Yang Z, et al. · Neurooncol Adv 2024
- Activation of Epstein-Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide.
Hartman-Houstman H, Swenson S, Minea RO, et al. · Cancers (Basel) 2024
- NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity.
Chen TC, Minea RO, Swenson S, et al. · Cancers (Basel) 2022
- Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia.
Schönthal AH, Swenson S, Minea RO, et al. · Cancers (Basel) 2021
- Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice.
Cho HY, Swenson S, Thein TZ, et al. · Neurooncol Adv 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.